{"id":"over-encapsulated-efavirenz","safety":{"commonSideEffects":[{"rate":"28-35","effect":"Dizziness"},{"rate":"25-30","effect":"Impaired concentration"},{"rate":"16-21","effect":"Insomnia"},{"rate":"16-26","effect":"Rash"},{"rate":"8-16","effect":"Nausea"},{"rate":"13-22","effect":"Headache"},{"rate":"7-14","effect":"Abnormal dreams"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV replication by inhibiting reverse transcriptase. The over-encapsulation technology delays and reduces the rate of drug absorption, lowering peak concentrations and potentially reducing neuropsychiatric adverse effects associated with high CNS penetration while maintaining therapeutic efficacy.","oneSentence":"Over-encapsulated efavirenz is a reformulation of the HIV reverse transcriptase inhibitor efavirenz designed to improve tolerability by reducing peak plasma concentrations and CNS exposure through modified-release encapsulation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:59:09.905Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (as part of combination antiretroviral therapy)"}]},"trialDetails":[{"nctId":"NCT01087814","phase":"PHASE4","title":"Sustiva Levels With Use of a Gel Capsule","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2010-02","conditions":"HIV, HIV Infections","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Over-encapsulated Sustiva"],"phase":"marketed","status":"active","brandName":"Over-encapsulated efavirenz","genericName":"Over-encapsulated efavirenz","companyName":"University of Minnesota","companyId":"university-of-minnesota","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Over-encapsulated efavirenz is a reformulation of the HIV reverse transcriptase inhibitor efavirenz designed to improve tolerability by reducing peak plasma concentrations and CNS exposure through modified-release encapsulation. Used for HIV-1 infection (as part of combination antiretroviral therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}